Objective: To compare cost and perioperative outcomes of robotic, videoassisted thoracoscopic surgery (VATS), and open surgical approaches to pulmonary lobectomy.
Results: A total of 697 patients underwent pulmonary lobectomy by robotic (n ¼ Value consideration of robotic, VATS, and open pulmonary lobectomy.
Central Message
Minimally invasive lobectomy is associated with superior clinical outcomes and similar hospital cost as compared with open lobectomy, with no significant difference between the robotic and VATS approach.
Perspective
In a propensity score-weighted analysis, we have found no significant difference in total cost to the hospital between robotic, VATS, and open lobectomy. Greater procedural cost of minimally invasive lobectomy was recovered in the postoperative period. The improved clinical outcomes of both robotic and VATS compared with open lobectomy are important when considering the overall value of minimally invasive procedures.
See Commentary on page 2027.
Pulmonary lobectomy remains the most commonly performed major operation in general thoracic surgery practice. Over the last 2 decades, there has been a substantial evolution in surgical techniques. Currently, there are multiple established approaches that are all frequently performed. In the most recent nationwide report of lobectomy for lung cancer from the National Cancer Database, the majority of lobectomies, up to year 2012, were performed via thoracotomy. 1 Adoption of minimally invasive lobectomy by video-assisted thoracoscopic surgery (VATS) has been gradually increasing and more recently propelled after the introduction robotic-assisted thoracoscopic (robotic) lobectomy. 2 With multiple established techniques, and little existing randomized data, controversy remains about the best approach. Although it is widely accepted that minimally invasive lobectomy is associated with improved perioperative outcomes, the utility of the robotics remains most controversial. [3] [4] [5] [6] Among surgeons who have mastered the VATS approach, the robotic technology can be viewed as unnecessary and expensive equipment. 7, 8 Other surgeons have embraced robotics due to the improved optics, the full control of the operating surgeon, and the use of precise wristed instruments with increased freedom of motion. 9, 10 In the current era of bundled payments and value-based care, surgeons are faced with increasing scrutiny to perform procedures associated with the best possible outcomes relative to dollars spent, 11 and hospitals are carefully considering investments in expensive technology. 12 Previous head-to-head comparisons of lobectomy approaches, including those of the early robotic experience, have indicated notable differences in cost. [13] [14] [15] [16] However, since the experience with robotic lung surgery has since evolved, these data may not accurately reflect the current outcomes and associated cost at high-volume centers. At our institution, we have gained substantial experience in robotic lung surgery and have continued to use VATS and open techniques to pulmonary lobectomy per preference of the individual surgeons. We hypothesize, that based on our current outcomes, there are no differences in overall cost to the hospital for robotic, VATS, and open lobectomy.
In this study, we sought to evaluate the hospital cost and outcomes of pulmonary lobectomy by robotic, VATS, and open thoracotomy approach performed and aim to overcome inherent differences in patient selection by statistical means of a propensity score weighted analysis.
METHODS
Patients who underwent pulmonary lobectomy between January 1, 2012, and September 1, 2017, were identified from the prospectively maintained institutional Society of Thoracic Surgery (STS) General Thoracic Surgery Database. We included all patients older than the age of 18 years with available financial data. Patients undergoing elective lobectomy for cancer or benign disease were included. We excluded patients who underwent sublobar resection, bronchoplastic resection, bilobectomy, or completion pneumonectomy. Pancoast tumors or concomitant chest wall resections were also excluded. Demographics, clinical, and outcomes data were extracted from the STS-General Thoracic Surgery Database. Definition of patient risk factors and postoperative events was defined by the STS Version 2.3 training manual. 17 Major complications were assessed as the incidence of any major adverse outcome as previously described. 18 Operative time was assessed as time from procedure start, typically a bronchoscopy, to completion of the operation following skin closure. Clinical data were then linked to hospital financial data provided by the billing department. The study was approved by our institutional review board with waiver of individual patient consent.
Comparison Groups
Patients were grouped by operative approach, distinguishing (1) robotic, (2) VATS, and (3) open thoracotomy. Selection of surgical approach was at the discretion of the treating surgeon. All procedures were performed by a group of board-certified thoracic surgeons and involved training surgical residents and cardiothoracic fellows. The experience level with minimally invasive techniques varied between the individual surgeons and evolved during the study period. The group included 3 high-volume minimally invasive surgeons, 1 primarily robotics surgeon, and 2 surgeons who have transitioned from VATS to robotics as the preferred approach for lobectomy within the study period. Although most surgeons have contributed to robotic, VATS, and open lobectomies in this cohort, 2 surgeons primarily performed open lobectomies.
Robotic lobectomy was performed using 4 instrument ports and an additional port for the bedside assistant. The da Vinci Si robot was initially used and replaced by the Xi model (Intuitive Surgical, Sunnyvale, Calif) in 2016. The majority of VATS cases were performed using a port-based approach with 4 ports, or a 3-incision McKenna technique. 19 Manual stapling was used in early robotic and all VATS and open lobectomies. Since 2016, we have also used the EndoWrist controlled staplers (Intuitive Surgical) for robotic lobectomies. Postoperative management was not protocolized but was guided by universal postoperative goals, including extubation in the operative room, recovery on a dedicated thoracic nursing wards, and chest tube removal before discharge, as previously described. 20 
Measures of Cost and Clinical Effectiveness
The primary financial outcome was total direct hospital cost. Secondary cost outcomes were total indirect cost specific to our institution and charges to the payor. Costs reflect the sum of all expenses to the hospital for the index stay for lobectomy, as provided by the billing department in US dollars. Both fixed and variable costs were included. Costs were determined at the discharge level and do not include outpatient expenses inquired for preoperative of postoperative care or readmissions. Total direct costs are defined as cost traceable to specific cost objects in the care of patients, including the price for any item used, facility occupied (operating room, hospital bed, etc), and service provided to conduct the operation and throughout the hospital stay. Total indirect costs are the sum of all additional costs for the hospital that is comprised of overhead cost and amortization of capital equipment, including of the purchase and maintenance of minimally invasive platforms, as previously outlined. 21 Operating room cost as a fraction of total direct hospital cost was available for years 2012 to 2015. After 2015, cost data were available on a more granular level by cost centers, which were compared separately. Charges were defined as the total dollar amount billed to the payor for the index hospitalization. Clinical effectiveness was measured by perioperative outcomes, taking into account length of stay, complications, and 30-day mortality.
Statistical Analysis
Categorical variables were summarized as frequencies and percentages. Crude comparisons were made between surgery groups using c 2 tests or and analysis of variance was used to test for differences between surgery groups. To account for treatment selection bias, we attempted to balance the baseline characteristics and surgical risk factors between the 3 lobectomy groups using a propensity score methodology with inverse probability of treatment weighing (IPTW). 22 The IPTWs were estimated using multinomial logistic regression analysis including the following differential variables (P .15), and disregarding outcomes: age, primary payor, American Society of Anesthesiologists (ASA) score, hypertension, diabetes, coronary artery disease, peripheral vascular disease, preoperative chemotherapy, preoperative thoracic radiation, prior cardiothoracic surgery, history of cerebrovascular accident, chronic obstructive lung disease, preoperative forced expiratory volume in 1 second, diffusion capacity for carbon monoxide, last preoperative hemoglobin and creatinine, presence of cancer, clinical tumor and nodal stage, and lobe resected. Complete data for these variables were available for 87.7% of patients. Data were assumed to be missing at random.
Multivariate normal imputation using SAS Proc MI was carried out to impute 10 data sets with imputed values for missing baseline characteristics that were then used to calculate the IPTWs for each patient. Inverse probability of treatment weights was calculated for each patient in each of the imputed data sets. The mean stabilized weights for each patient from the 10 data sets were used as the final IPTWs. Patients with overweighted IPTWs (scores >15) were excluded from the adjusted analyses, which was the case for 1 patient in the VATS group. Patient characteristics were then reassessed for balance between surgery groups after adjusting for the IPTWs.
Baseline categorical variables and perioperative outcomes were compared between surgery groups after adjusting for IPTWs using RaoScott c 2 tests using the Surveyfreq procedure in SAS. The SAS Surveyreg procedure was used to fit IPTW adjusted linear regression models to test for differences in continuous variables between surgery groups for each outcome respectively. For pairwise comparison of cost endpoints, multiple comparisons of cohort differences were adjusted for using the TukeyKramer method. Cost outcomes were assessed on the natural log scale due to violations of the normality assumption on the original scale. To test the impact of conversions of minimally invasive to open procedures, we first excluded conversions in the cost analysis, and then repeated the analysis accounted for conversions in an intention-to-treat analysis. Hypothesis testing for main outcomes was conducted maintaining an overall 5% type I error rate. The statistical analysis was designed and conducted by a biostatistician (M.A.) using SAS version 9.4 (SAS Institute, Cary, NC).
RESULTS

Patient Characteristics
A total of 697 patients who fulfilled the selection criteria underwent lobectomy completed by robotic (n ¼ 296) and VATS (n ¼ 161) or open thoracotomy (n ¼ 240) approach. Forty-one patients were converted from robotic approach to thoracotomy and 21 from VATS to thoracotomy. A Consolidated Standards of Reporting Trials diagram detailing the patient selection is provided as Figure E1 . Patient demographics and clinical characteristics before and after propensity weighing are summarized in Table 1 . Before the propensity weighing, the robotic, VATS, and open cohorts differed in multiple variables, including age, insurance/payor status, ASA score, comorbidities, pulmonary function test, resection following previous (Table 1) .
Perioperative Outcomes
A comparison of crude and IPTW-adjusted perioperative outcomes by approach is presented in Table 2 . The unadjusted rate of any complication (robotic 46% vs VATS 39% vs open 56%, P ¼ .002) and major complication (robotic 12% vs VATS 6% vs open 16%, P ¼ .006) were lowest in the VATS group and greatest in the open thoracotomy group. After IPTW adjustment, these differences were 
Cost Comparison
A propensity-adjusted cost comparison by surgical approach is presented in Table 3 , and the unadjusted analysis is provided in Figure E2 ). There was also no difference in total indirect cost (Table 3) .
Cost comparisons remained unchanged when considering conversions of minimally invasive procedures, assessed by an intention-to-treat analysis (Table E2) . Operating room cost of robotic lobectomy was significantly greater than for open but similar to VATS lobectomy. A detailed breakdown of proportional costs by the various cost centers is compared in Table 4 . We observed an inverse relationship between operating room cost and the cost for the hospital room and nursing among the 3 groups. Robotic 
DISCUSSION
The high cost of robotic surgery has been a main point of criticism since the early adoption of robotic-assisted lung resection and has raised the question of its value. In this retrospective study of a large single-institution experience, we demonstrate that there were no significant differences in hospital cost or charges to the payor among roboticassisted, VATS, and open lobectomies in a propensity weight-adjusted analysis. The clinical effectiveness of robotic lobectomy as measured by length of stay and postoperative events was similar to that of the VATS cases. The clinical outcomes of both minimally invasive procedures compared favorably with open thoracotomy, with reduced pulmonary complications and decreased length of stay, even after carefully controlling for patient selection (Graphical Abstract, Video 1). In a recent systematic review of published studies on cost of robotic lobectomy, we have shown that there is great variability among institutions, ranging between $15,440 and $22,582 for median hospital cost. 21 We showed that the greatest hospital costs of robotic lobectomy were calculated from registry data, reflecting the early robotic experience. 7, 13 By contrast, the lowest costs associated with robotic lobectomy were reported from a high-volume center, which also reported the lowest complication rates and shortest hospital stay. 15 A previous analysis of factors associated with cost of lobectomy showed that the additive cost of postoperative events had a substantial impact on overall hospital cost following lobectomy, which increased by 23%, 53%, and 185% with 1, 2, and 3 complications, respectively. 23 Improvements of postoperative outcomes therefore have a notable impact on overall cost-effectiveness. 20 In one of the first cost-effectiveness studies, Burfeind and colleagues 24 also reported on cost savings and at a single center with high volume of VATS. Swanson and others 16 confirmed that increased operating room cost of VATS lobectomy can be mitigated by improved postoperative outcomes in a multi-institution analysis. Our current analysis confirms that procedural cost in the operating room remains lowest with open procedures, as it is associated with the shortest operating room times and the least expensive equipment. However, even after carefully adjusting for patient selection, both robotic and VATS approaches were associated with shorter length of stay and fewer costly events, and, as a result, in similar overall hospital cost. Robotic lobectomy cases had the greatest operating room costs, which were proportionally recovered by savings in the postoperative period (Figure 1) .
Our results of cost comparison of robotic and VATS lobectomy differ from those of previous studies, which were derived from the early experience of the robotic lobectomy. 7, 13, 14 Overall costs were greater than 2 large registry studies, which found that robotic lobectomy was more costly than VATS lobectomy, whereas there was no significant difference in this current study: Paul and colleagues 13 compared the outcomes of the early experience of robotic to VATS lobectomy using the National Inpatient Sample and found greater complication rates with robotic lobectomy, with an estimated cost increase of 26%. Similarly, Swanson and colleagues 7 found a that cost of robotic lobectomy resulted in nearly 22% greater hospital cost than for VATS lobectomy in the Premier Database, which was associated with longer operating times for robotic procedures. These studies pooled cases from the early robotic experience (years 2008-2011) . In a more recent, small single institution study, Deen and colleagues 8 compared hospital costs of 57 robotic with 58 VATS lobectomies and showed that robotic cases were still more expensive, with greater costs derived from longer operative times and the added cost of roboticspecific supplies and depreciation. In the present study, we show that with shorter operative times and similar outcomes, robotic lobectomy can be performed with similar cost as compared with the VATS approach.
Looking beyond the perspective of hospital economics, it is evident that the choice of surgical approach may have a broader impact on health economics and the surgical community. A recent study by Watson and Qiu 25 used a large commercial insurance claims database to examine differences of thoracoscopic and open lobectomies. Although their comparison was not adjusted for patient selection, it showed that the thoracoscopic approach was associated with less resource use. They demonstrated a 24% lower use of health care days within 90 days and 14% less resource use in the first operative year, which points to potential cost savings beyond the index hospitalization. 25 Robotic lobectomy cases were likely included in the thoracoscopic group, because there was no specific Current Procedural Terminology code. Although few studies to date have compared hospital charges to the payor, one previous study had concluded that total hospital charges of robotic lobectomy exceeded those of VATS lobectomy by 45% 13 in the early robotic experience, possibly due to the reported greater intraoperative and bleeding complication rates. In our current study, we show that with similar outcomes between robotic and VATS procedures, total hospital charges of robotic, VATS, and open lobectomy were similar in the adjusted analysis.
Finally, our data are perhaps most impactful from the perspective of the individual cost-considerate surgeon. Our results indicate that primary criterion of selection of the lobectomy approach should be driven by the surgeon's experience and comfort level. Although cost should remain a consideration, it should not dictate the surgical approach. This is by reason that in the overall in-hospital equation, postoperative outcomes appear to be the main determinant of cost and ultimately determine what benefits patients. As for many innovative procedures, the true value of robotic lobectomy may not be apparent at first. The upfront capital cost of the robotic technology remains high in the current single manufacturer market, and the clinical outcomes have not been proven to be significantly better compared with the VATS approach. Until the price of technology decreases, which is expected in the near future with the arrival new platforms of competing manufacturers, surgeons may need to continue to debate over the utility of using robotics. We recognize that the realization of economies of scale at our institution is likely the result of a system-wide commitment to robotic surgery and the work of a dedicated robotics team with continued process improvement efforts. As such, the operative time of robotic lobectomy has been reduced to an average duration shorter than that of VATS lobectomy, and recovery has been streamlined. With growing experience of robotic thoracic surgery, additional important benefits are now being recognized in the surgical community. This includes the steep learning curve of trainees, resulting in increased competency of minimally invasive lobectomy.
Particular strengths of this study include the large number of patients treated at a single institution with detailed clinical data and the use of propensity scores to adjust for differences in selection in the comparison of the 3 approaches to lobectomy. There are, however, several limitations that must be considered when interpreting our results. As a result of the observational study design, unmeasured confounders cannot be completely excluded and may have influenced the comparison between groups. With regard to outcomes and cost, we have made every effort to control for differences in patient factors and known STS risk factors. However, there may other salient patient or disease factors that were not accounted for and could have influenced the selection of the operative approach. The groups are not randomized, and therefore the biases and experiences of individual surgeons, as well as the degree of trainee involvement, could have influenced the study results. Regarding the cost endpoints, we have provided a detailed analysis at the hospital level. Cost of postdischarge health care use, including readmissions and rehabilitation services were not considered and may have additional implications from a health economic standpoint. Financial analysis may not be directly comparable with other institutions, because cost factors may vary significantly between hospital systems. For example, other institutions may face different capital deprivation and amortization of the robot based on the overall volume of robotic cases. Comparability of absolute hospital cost between studies is further challenged by different cost definitions and time periods between studies. As such, the absolute cost figures presented, may appear higher or lower in this study as compared with some previous reports. Indirect cost in particular may differ most, based on the institutional economic conditions and operative volume. Lastly, this study is limited to comparison of hospital outcome measures and does not account for differences in patient reported outcomes and oncologic endpoints.
CONCLUSIONS
There were no significant differences in hospital cost or charges between the robotic-assisted, VATS, and open lobectomy. Increased procedural cost of minimally invasive lobectomy can be recovered in the postoperative period, associated
The Journal of Thoracic and Cardiovascular Surgery c Volume 157, Number 5 
